UNIV OF TX SOUTHWESTERN COMPREHENSIVE MED SICKLE CELL CT

德克萨斯大学西南综合医学镰状细胞 CT

• 批准号: 7463037
• 负责人: GEORGE R BUCHANAN
• 金额: $ 9.48万
• 依托单位: UT SOUTHWESTERN MEDICAL CENTER
• 依托单位国家: 美国
• 财政年份: 2003
• 资助国家: 美国
• 起止时间: 2003-07-01 至 2008-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7463037
• 关键词: Adolescent; Adult; Advocacy; Applications Grants; Arts; Basic Science; Caring; Child; Childhood; Clinical; Clinical Research; Clinical Trials; Education; Enrollment; Florida; Funding; Grant; Health Sciences; Health Services Research; Human Resources; Infant; Institution; Lead; Medical; Medical center; Medicine; Oklahoma; Patient Care; Patients; Persons; Physicians; Play; Protocols documentation; Purpose; Qualifying; Research; Research Personnel; Research Project Grants; Role; Services; Sickle Cell; Sickle Cell Anemia; Site; Solid; Southwestern United States; Texas; Time; Universities; base; college; design; novel; patient oriented research; programs; success

Center Overview The Southwestern Comprehensive Sickle Cell Center (the "Center"), which has served as one of the ten NHLBI-funded Centers during 2003-2008 grant cycle, is applying for continued support during the next funding cycle. The Center, based at the University of Texas Southwestern Medical Center at Dallas (UT Southwestern) and Children's Medical Center Dallas (CMCD), will continue to include other collaborating medical centers whose physicians and other personnel are dedicated to the care of persons with sickle cell disease and the conduct of novel clinical, translational, and health services research. These other Centers are the University of Texas at Dallas, the University of Oklahoma Health Sciences Center, the University of Texas Medical Branch at Galveston, and the University of Florida College of Medicine. The Center's track record during the current grant period in the CSCC Clinical Trials Consortium has been exemplary. Center investigators lead two of the five national clinical trials opened thus far and play prominent roles on Consortium committees. Moreover, clinical trial enrollment from the multiple sites in our Center has been substantial. The Center currently ranks second overall among the ten comprehensive centers in patient enrollment. The Center is also successfully executing basic science, clinical intra-Center, and a variety of other collaborative and institutional research protocols, accompanied by smoothly functioning administrative and patient services cores. The Center plans to continue and appreciably expand myriad research, patient care, education, and advocacy initiatives during the next five years. A cohesive, interactive, and collaborative spirit exists among Center investigators and their institutions, thus assuring the Southwestern Comprehensive Sickle Cell Center's continued success.

中心概况 西南综合性镰状细胞中心（“中心”），该中心曾担任十个 在2003-2008年赠款周期期间，NHLBI资助的中心正在申请下一个周期的继续支持。 融资周期。该中心位于德克萨斯大学西南医学中心，位于达拉斯（UT 西南）和儿童医疗中心达拉斯（CMCD），将继续包括其他合作 医疗中心，其医生和其他人员致力于镰状细胞病患者的护理 疾病和新的临床，转化和卫生服务研究的行为。这些其他中心 分别是德克萨斯大学达拉斯分校、俄克拉荷马州大学健康科学中心、 位于加尔维斯顿的德克萨斯医学分支和佛罗里达大学医学院。中心的轨道 CSCC临床试验联盟在当前资助期间的记录堪称典范。中心 迄今为止，研究人员领导了五项国家临床试验中的两项，并在以下方面发挥了重要作用： 财团委员会。此外，我们中心的多个研究中心的临床试验入组人数已 相当可观该中心目前在10个综合性中心中排名第二， 招生该中心还成功地开展了基础科学、临床中心内以及各种 其他合作和机构研究协议，伴随着顺利运作的行政管理 和患者服务核心。该中心计划继续并明显扩大无数的研究，病人 在未来五年内开展护理、教育和宣传活动。一个有凝聚力的，互动的， 中心研究人员及其机构之间存在合作精神，从而确保西南地区 综合性镰状细胞中心的持续成功。